
Josee-Lyne Ethier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7521188/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The needs of gynecological cancer survivors at the end of primary treatment: A scoping review and proposed model to guide clinical discussions. Patient Education and Counseling, 2022, 105, 1761-1782.	1.0	11
2	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology, 2022, 29, 231-242.	0.9	3
3	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer, 2021, 149, 117-127.	1.3	7
4	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 162, 103324.	2.0	6
5	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i> -Positive Metastatic Breast Cancer. JAMA Oncology, 2021, 7, e212140.	3.4	12
6	The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions. Journal of Adolescent and Young Adult Oncology, 2019, 8, 547-553.	0.7	7
7	Perceived Barriers to Goals of Care Discussions With Patients With Advanced Cancer and Their Families in the Ambulatory Setting. Journal of Palliative Care, 2018, 33, 125-142.	0.4	53
8	Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. Clinical Oncology, 2018, 30, 215-224.	0.6	28
9	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology, 2017, 145, 584-594.	0.6	85
10	Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. Current Oncology Reports, 2017, 19, 15.	1.8	1
11	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer, 2017, 77, 40-47.	1.3	52
12	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 53, 120-127.	3.4	178
13	Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology, 2017, 147, 158-166.	0.6	71
14	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research, 2017, 19, 2.	2.2	457
15	The role of cediranib in ovarian cancer: current status and further investigation. Expert Opinion on Orphan Drugs, 2016, 4, 855-865.	0.5	0
16	The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment. Molecular Diagnosis and Therapy, 2016, 20, 307-313.	1.6	6
17	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. PLoS ONE, 2015, 10, e0122735.	1.1	14
18	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. Journal of Clinical Oncology, 2015, 33, 100-106.	0.8	47

#	Article	IF	CITATIONS
19	A systematic review and quality appraisal of international guidelines for early breast cancer systemic therapy: Are recommendations sensitive to different global resources?. Breast, 2015, 24, 309-317.	0.9	7